Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.45 |
| ▸ | DHODH | Q02127 | 3/20 | 0.45 |
| ▸ | USP7 | Q93009 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17620557 | 0.90 | KDM4E (0.40) | RAD51DHODHPDE10AALDH1A1 | |
| SCHEMBL17620587 | 0.87 | KDM4E (0.49) | MEN1KMT2APOLBTNKSGUSB | |
| SCHEMBL22449438 | 0.87 | RAD51 (0.50) | MEN1KMT2ARAD51TNKSPARP1 | |
| SCHEMBL17620591 | 0.87 | NPC1 (0.44) | RAD51TNKSTNKS2ALDH1A1 | |
| SCHEMBL17620569 | 0.87 | CYP19A1 (0.47) | MEN1KMT2ARAD51TNKSTNKS2 | |
| SCHEMBL17620578 | 0.87 | TDP1 (0.49) | POLBTNKSPARP1TNKS2ALDH1A1 | |
| SCHEMBL21656455 | 0.87 | RAD51 (0.38) | MEN1KMT2ARAD51DHODHALDH1A1 | |
| SCHEMBL17620562 | 0.84 | RAB9A (0.40) | RAD51DHODHPOLBESR1ALDH1A1 | |
| SCHEMBL18396441 | 0.84 | RAD51 (0.53) | MEN1KMT2ARAD51GUSBTNK2 | |
| SCHEMBL17620548 | 0.84 | KDM4E (0.52) | MEN1KMT2AUSP7POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2020-09-29 | — | — | US | claimed |
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2020-09-29 | — | — | US | disclosed |
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | DNA2, IRF3, DDB1 | MEN1 3101/4885KMT2A 3767/4885RAD51 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.